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Abstract
The endotelin (ET) axis, that includes ET-1, ET-2, ET-3, and the ET receptors, ETA and ETB, plays
an important physiological role, as modulator of vasomotor tone, tissue differentiation and
development, cell proliferation, and hormone production. Recently, investigations into the role of
the ET axis in mitogenesis, apoptosis inhibition, invasiveness, angiogenesis and bone remodeling
have provided evidence of the importance of the ET-1 axis in cancer. Data suggest that ET-1
participates in the growth and progression of a variety of tumors such as prostatic, ovarian, renal,
pulmonary, colorectal, cervical, breast carcinoma, Kaposi's sarcoma, brain tumors, melanoma, and
bone metastases. ET-1 receptor antagonists beside providing ideal tools for dissecting the ET axis
at molecular level have demonstrated their potential in developing novel therapeutic opportunity.
The major relevance of ETA receptor in tumor development has led to an extensive search of highly
selective antagonists. Atrasentan, one of such antagonists, is orally bioavailable, has suitable
pharmacokinetic and toxicity profiles for clinical use. Preliminary data from clinical trials
investigating atrasentan in patients with prostate cancer are encouraging. This large body of
evidence demonstrates the antitumor activity of endothelin receptor antagonists and provides a
rationale for the clinical evaluation of these molecules alone and in combination with cytotoxic
drugs or molecular inhibitors leading to a new generation of anticancer therapies targeting
endothelin receptors.
Introduction
The endothelins, that includes three 21-aa peptides ET-1,
ET-2 and ET-3, are potent vasoconstricting peptides,
involved in the pathophysiology of different malignancies
[1,2]. ET-1 is a relevant growth factor in several tumor
types including carcinoma of the prostate, ovary, colon,
cervix, breast, kidney, lung, colon, central nervous system
(CNS) tumors as well as melanoma, Kaposi's sarcoma
(KS) and bone metastasis [3]. ETs and their receptors have
been implicated in cancer progression through autocrine
and paracrine pathways [4]. ET-1 participates to a wide
range of cancer relevant process, such as cell proliferation,
inhibition of apoptosis, matrix remodeling, bone deposi-
tion, and metastases. The demonstration of ET-1 as an
important mediator in the progression of many tumors
clearly identifies the ET axis as a potential therapeutic tar-
get. This has propelled the development of several potent
and selective ET-1 receptor antagonists. These small mol-
ecules have contributed to our understanding of the phys-
iopathological relevance of the ET axis and the beginning
of translation of this information into clinical trials [5,6].
Pathophysiology of endothelin
Synthesis
ET-1, ET-2 and ET-3, are characterized by a single α-helix
and two disulfide bridges. The three peptides are encoded
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by distinct genes and are regulated at the level of mRNA
transcription. The primary translation product of the ET-1
gene is the 212-aa prepro-ET-1, which is cleaved by an
endopeptidase to form the 38-aa big-ET-1. The biologi-
cally active ET-1 is formed by endothelin-converting-
enzyme (ECE), an enzyme with intracellular and mem-
brane-bound isoforms [7]. The half-life of ET-1 in circula-
tion is seven minutes [8]. Two pathways have been
described for clearance of endothelin: ETB receptor-medi-
ated uptake followed by lisosomal degradation [9,10] and
catabolism by extracellular neutral endopeptidase (NEP)
[11,12]. ET-1 production is stimulated by a variety of
cytokines and growth factors, including IL-1β, TNF-α,
TGF-β, PDGF, vasopressin, hypoxia, and shear stress.
Inhibitory factors include nitric oxide, prostacyclin and
atrial natriuretic peptide [6].
Receptors and signaling pathways
Endothelins exert their effects by binding to two distinct
cell surface ET receptors, ETA and ETB. The ETB receptor
(ETBR) binds the three peptide isotypes with equal affin-
ity. In contrast, ETAR binds ET-1 with higher affinity than
the other isoforms. Both receptors belong to the G pro-
tein-coupled receptor (GPCR) system and mediates bio-
logical responses from a variety of stimuli, including
growth factors, vasoactive polypeptides, neurotransmit-
ters, hormones, and phospholipids [1,2].
ET-1 is produced by a variety of normal cells, including
endothelial cells, vascular smooth muscle cells, and vari-
ous epithelial tissues (eg, bronchial, endometrial, mam-
mary, and prostatic) and is mitogenic for a variety of cell
types including endothelial cells, vascular and bronchial
smooth muscle cells, fibroblasts, keratinocytes, mesangial
cells, osteoblasts, melanocytes, and endometrial stromal
cells. This peptide, which is the most common circulating
form of ETs, is produced also by many epithelial tumors
where it acts as an autocrine or paracrine growth factor
[4]. Ligand binding to the endothelin receptor results in
activation of a pertussis toxin-insensitive G protein that
stimulates phospholipase C activity and increases intrac-
ellular Ca2+ levels, activation of protein kinase C, mitogen
activated protein kinase (MAPK) and p125 focal adhesion
kinase (FAK) phosphorylation. Among downstream
events after endothelin receptor activation, ET-1 causes
EGF receptor transactivation, which is partly responsible
for MAPK activation [13,14].
Endothelin axis in tumor
ET-1 and tumor cell proliferation
ET-1 stimulates DNA synthesis and cell proliferation in
various cells, including vascular smooth muscle, osteob-
lasts, glomerular mesangial cells, fibroblasts and melano-
cytes. ET-1 is also a mitogen for different cell types
including prostate, cervical, ovary cancer cells. In primary
cultures and established ovarian carcinoma cell lines,
spontaneous growth was significantly inhibited in the
presence of ETAR antagonist. ETBR antagonist lacked this
activity demostrating that endogenous ET-1 acts as an
autocrine modulator of ovarian carcinoma cell prolifera-
tion only through ETAR [15].
The mitogenic activity of ET-1 can be amplified by syner-
gistic interactions with other growth factors including epi-
dermal growth factor (EGF), basic fibroblast growth factor
(bFGF), insulin, insulin-like growth factor (IGF), platelet-
derived growth factor (PDGF), transforming growth factor
(TGF), and interleukin-6 (IL-6) [16].
ET-1 and tumor neovascularization
ETs, which are mitogens for endothelial cells, vascular
smooth muscle, fibroblasts, and pericytes, are also ang-
iogenic factors. Endothelial cell mitogenesis is mediated
by ETBR, while vascular smooth muscle cells and pericyte
mitogenesis is mediated predominantly or solely by the
ETAR. ET-1 modulates various stages of neovasculariza-
tion, including endothelial cell proliferation, migration,
invasion, protease production, tube formation and stimu-
lates neovascularization in vivo [17]. Elevated expression
of ET-1 and its cognate receptor is significantly associated
with microvessel density (MVD) and vascular endothelial
growth factor (VEGF) expression in ovarian carcinomas
[18], suggesting that ET-1 and VEGF might have a comple-
mentary and coordinated role during neovascularization
in this tumor. Thus, in ovarian carcinoma cell lines, ET-1
increases VEGF mRNA expression and induces VEGF lev-
els in a time- and dose-dependent fashion, and does so to
a greater extent during hypoxia. These activities were
mediated through the ETAR, because the specific antago-
nist, BQ 123, reversed the stimulation of VEGF produc-
tion [18].
The transcriptional upregulation of VEGF has been linked
to a critical mediator of hypoxia signaling, the hypoxic
inducible factor-1α (HIF-1α). ET-1 promotes VEGF pro-
duction through HIF-1α and this mechanism might be
responsible for increasing tumor angiogenesis. Degrada-
tion of HIF-1α was infact reduced in ET-1-treated ovarian
carcinoma cells under both hypoxic and normoxic condi-
tions. After ET-1 stimulation, HIF-1α protein levels
increase in the cells, the HIF-1 transcription complex is
formed and binds to the HRE binding site. Therefore, ET-
1-induced HIF-1 accumulation activates all the signals
necessary for a complete HIF-1 response [19]. The HIF-1α-
mediated transcription of VEGF by ET-1 under normoxic
conditions points to a general mechanism through which
oncogenes and growth factors might upregulate VEGF,
and could synergize with hypoxia during tumor growth.
Addition of a specific ETAR antagonist blocked the ET-1-
induced upregulation of VEGF expression and secretion asJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/16
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well as the ET-1-induced activation of HIF-1 transcription
complex. In tumor cells, ET-1 might be upregulated by
hypoxia and could promote angiogenesis by increasing
VEGF production through an HIF-1α-dependent mecha-
nism. Thus, under hypoxic conditions, ET-1 potentiates
hypoxia stimulus by amplifying HIF-1α stability and
VEGF production [25].
Prostaglandins (PG) and their rate-limiting enzymes
cyclooxygenase (COX)-1 and -2 are involved in the onset
and progression of a variety of malignancies [21]. Moreo-
ver high COX-1 and -2 have been reported in association
with elevated levels of proangiogenic factors in ovarian
cancer [22-25]. In ovarian carcinoma cells, ET-1 signifi-
cantly increases the expression of COX-1 and -2, at mRNA
and protein level, the COX-2 promoter activity and PGE2
production. These effects depend on the ETAR activation
and involve multiple MAPK signal pathways, including
p42/44 MAPK, p38 MAPK and the transactivation of
EGFR.
There is increasing evidence that PGE2  contributes to
tumor progression also by promoting angiogenesis and
that this effect is mediated by VEGF. COX-2 and-1 inhibi-
tors blocked ET-1-induced PGE2 and VEGF release dem-
onstrating that both enzymes, although by a different
extent, participate to PGE2 and VEGF production. These
results indicate that impairing COX-1 and -2 and their
downstream effect by targeting ETAR can be therapeuti-
cally advantageous [26] also in view that elevated COX-2
levels are associated with tumor progression and chem-
oresistance [24].
ET-1 and apoptosis
ET-1 is an antiapoptotic factor in different cell types, indi-
cating that the peptide may also modulate cell survival
pathways. In ovarian carcinoma cells, the addition of ET-
1 markedly inhibited serum-withdrawal and paclitaxel-
induced apoptosis in a concentration-dependent manner.
Paclitaxel-induced apoptosis resulted in the phosphoryla-
tion of Bcl-2 that was suppressed by the addition of ET-1.
Further analysis of the survival pathway demonstrated
that ET-1 stimulated Akt activation dependent on PI3-K.
Interestingly, the addition of a specific ETAR antagonist
blocked the ET-1-induced resistance to paclitaxel-medi-
ated apoptosis indicating that ET-1 contributes to trigger
resistance to paclitaxel through ETAR binding via activa-
tion of anti-apoptotic signaling pathways such as Akt.
Specific ETAR antagonists may therefore provide an addi-
tional approach to the treatment of ovarian carcinoma in
which ETAR blockade could result in the tumor growth
inhibition by reducing tumor growth as well as by induc-
ing apoptosis. Furthermore when combined with the con-
ventional chemotherapy the ETAR antagonists would
more effectively induce apoptosis by contributing to the
reversal of paclitaxel resistance [27].
ET-1 and tumor invasion
As mentioned, high levels of ET-1 are detected in the
majority of ascitic fluids of ovarian cancer patients and are
significantly correlated with VEGF ascitic concentrations,
suggesting that ET-1 may enhance the secretion of extra-
cellular matrix-degrading proteinases and metastatization
[18]. Thus, ET-1 acting through the ETAR consistently
induced the activity of two families of metastasis-related
proteinases, the matrix metalloproteinases (MMPs) and
the urokinase type plasminogen activator system at sev-
eral levels: mRNA transcription, zymogen secretion and
pro-enzymes activation. ET-1 in fact activates MMP-2,
MMP-9, MMP-3, MMP-7 and MMP-13. In addition to sol-
uble MMPs, ET-1 enhanced the activation of MT1-MMP
and the secretion of tissue inibitor of MMP (TIMP-1 and -
2) increasing the net MMP/TIMP balance and the gelati-
nolytic capacity that results in rapid degradation of extra-
cellular matrix (ECM). In the ovarian carcinoma cells, co-
induction of uPA system, by the concomitant stimulation
of production and secretion of uPA and uPAR, and MMPs
by ET-1 resulted into the highest invasive potential of
tumor cells through the Matrigel. Interestingly, the addi-
tion of BQ 123 blocked the ET-1-induced proteinase acti-
vation and tumor cell migration and invasion.
Furthermore in these cells, ET-1 stimulated FAK and pax-
illin phosphorylation through ETAR binding [13] which
directly correlated with tumor cell migration and invasion
suggesting that ETAR antagonist can inhibit cell migration
and possibly other FAK-associated processes which also
contributes to invasion and metastasis in this tumor [28].
Following malignant transformation, stepwise changes in
intercellular communications enable tumor cells to
escape microenvironmental control from the normal sur-
rounding tissue, thus allowing local invasiveness and met-
astatization. Human ovarian surface epithelial cells
exhibit extensive gap junction intercellular communica-
tions (GJIC) and expression of different types of connexin
(Cx), predominantly Cx43. Defects in intercellular com-
munication, including reduced or inappropriate expres-
sion of Cx43 has emerged as key factors in ovarian
carcinoma progression. In ovarian carcinoma cells, ET-1
via ETAR induces a transient and a dose-dependent reduc-
tion of GJIC (50–75%) and phosphorylates Cx43 through
Src tyrosine kinase pathway indicating that ET-1 promotes
cellular uncoupling at the level of connexin maturation
and subsequent degradation [29]. The capacity of ET-1 to
disrupt gap junctions could serve as a basis to further eval-
uate the cell-cell metabolic uncoupling and the cell
detachment that occurs during tumor progression and
adds further information on the overall relevance of ETARJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/16
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in regulating the complex array of cell-cell or cell-matrix
interactions promoting ovarian carcinoma growth [29].
Osteogenesis
Several observations implicate ET-1 in the osteoblastic
response. Osteoblasts display a high density of ET recep-
tors, and respond to ET-1 by increasing synthesis of both
collagenous and noncollagenous proteins, including two
osteoblast messengers such as osteopontin and osteocal-
cin [30]. Osteoblasts are also sensitive to the mitogenic
and comitogenic activity of ET-1. Furthermore ET-1 inhib-
its osteoclasts activity and motility, upsetting the balance
of osteoblasts and osteoclasts to favor new bone forma-
tion [31]. Alkaline phosphatase, a marker of new bone
formation, is elevated in the presence of exogenous ET-1
[32]. ET-1 production is stimulated by IL-1β, TNF-α and
TGF-β, which are normally secreted by immunocompe-
tent cells, as well as osteoblasts and endothelial cells. This
suggests that paracrine mediators secreted by osteoblasts
and tumor cells are involved in a paracrine growth loop
that results in the derangement of bone remodelling.
Pain
ET-1 is described as a new pain mediator implicated in the
pathogenesis of pain states. Local cutaneous injection of
ET-1 causes pain and excitation of nociceptors, both phe-
nomena depending on ETAR. The peptide can trigger pain
through ETAR of local nociceptors, and concurrently pro-
duces analgesia through ETBR by inducing the release of β-
endorphin and the activation of opioid pool [33]. It is rea-
sonable to speculate that the refractory pain of certain
metastatic cancers is related to the direct nociceptive
effects of ET-1. Thus antagonist of ETAR have been shown
to ameliorate pain. This knowledge may lead to
improved, targeted analgesia in patients with advanced
cancer [34].
Targeting endothelin receptor as novel approach in cancer 
treatment
Ovarian carcinoma
Ovarian cancer is the leading cause of gynecologic cancer-
related death. ET-1/ETAR autocrine pathway is overex-
pressed in primary and metastatic ovarian carcinomas,
compared with normal ovaries (15). In view of the fact
that ETAR contributes to ovarian cancer progression by
inducing cell proliferation, survival, angiogenesis and
invasiveness, the ETAR has been proposed as a novel target
for anticancer therapy. The recent identification of high-
selective small molecules that inhibit ligand-induced acti-
vation of ETAR offers now the possibility of testing this
therapeutic approach in a clinical setting. Among various
ETAR antagonists, ABT-627 (atrasentan, Abbott Laborato-
ries, Abbott Park, IL) is an orally bioavailable endothelin
antagonist that potently (Ki = 34 pM) and selectively binds
to the ETAR, blocking signal transduction pathways impli-
cated in cancer cell proliferation and other host-depend-
ent processes promoting cancer growth (Figure 1).
In ovarian cancer, ABT-627 inhibits in vitro cell prolifera-
tion, the ET-1 mediated protection against paclitaxel-
induced apoptosis and the release of VEGF. A cooperative
proapoptotic and VEGF inhibitory effect was observed
when ABT-627 was used together with paclitaxel.
Treatment with ABT-627 produced a 65% tumor growth
inhibition in well established HEY xenografts. This treat-
ment which was generally well tolerated, with no detecta-
ble signs of acute or delayed toxicity was long-lasting and
comparable to that achieved by paclitaxel. More marked
and prolonged tumor growth inhibition (90% of con-
trols) was obtained by combined treatment of ABT-627
with paclitaxel, with no toxicity and with four complete
tumor regressions out of 10 treated animals. Immunohis-
tochemical analysis of the xenografts revealed a marked
reduction in the percentage of COX-2, VEGF and MMP-2
in treated mice. Tumor-induced vascularization, quanti-
fied as microvessel density (MVD) was directly propor-
tional to the expression of VEGF. A significant increase in
the percentage of TUNEL-positive cells was found [35].
The tumor growth inhibition induced by ABT-627, was
also associated with a reduction of Cx43 phosphorylation
and with an increase Cx43-based intercellular communi-
cation, suggesting that ETAR blockade may contribute to
the control of ovarian carcinoma growth and progression
also by preventing the loss of GJIC [29]. Almost complete
inhibition of VEGF, MMP-2 expression, and tumor neo-
vascularization, and an increase in apoptosis, were
observed following combined treatment of ABT-627 with
paclitaxel.
These findings demonstrating the antitumor, anti-ang-
iogenic, apoptotic activities of ABT-627 in vivo provide a
rationale for the clinical evaluation of this molecule,
alone and in combination with other therapies, in
patients with ovarian tumors and potentially in other epi-
thelial tumors that overexpress functional ETAR.
Prostate carcinoma
The ET axis has recently been identified as contributing to
the pathophysiology of prostate cancer [32,36,37]. In the
normal prostate gland, ET-1 is produced by epithelial
cells; the highest concentrations of ET-1 in the body are
found in seminal fluid. In prostate cancer, key compo-
nents of the ET-1 clearance pathway, ETB and neutral
endopeptidease (NEP), are diminished, resulting in an
increase in local ET-1 concentrations. Increased ETAR
expression is also seen with advancing tumor stage and
grade in both primary and metastatic prostate cancer.
There are multiple pathways by which the ET-1/ETA axis
may promote prostate cancer progression. In prostateJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/16
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cancer cell lines, ET-1 acting synergistically with other
peptide growth factors is a mitogen and modulates apop-
tosis by affecting cell survival. Selective ETAR antagonists
may block the proliferative effects of exogenous ET-1 in
both prostate cancer cells and osteoblasts. In a phase I
clinical trial, patients with advanced prostate cancer were
treated with atrasentan. In this trial stabilization and
decline of PSA occurred in 66% of patients. In a phase II
study, atrasentan suppressed markers of biochemical and
clinical prostate cancer progression in bone [38,39]. These
data substantiate the role of the ET-1/ETA axis as a growth
and survival factor and as a therapeutic target in hormone-
refractory prostate cancer. Atrasentan may inhibit tumor
growth in bone both by direct effects on the tumor cells
and by disrupting important bone/tumor interactions. In
a randomized double-blind phase II study, 288 patients
with hormone refractory prostate cancer were enrolled
and were treated with atrasentan 2.5 mg and 10 mg
administered orally once daily. In the evaluable patients
(n = 244), atrasentan significantly delayed time to clinical
and biochemical (PSA) progression. The most common
side effects included rhinitis, peripheral edema, and head-
ache. Atrasentan also maintained total and bone alkaline
phosphatase concentrations at baseline values compared
to the placebo-treated group. These findings suggest that
atrasentan may inhibit progression of hormone refractory
metastatic prostate cancer.
Osteoblastic bone metastases
Osteoblastic bone metastases occur in advanced prostate
and breast cancers, but the mechanism underlaying new
bone formation are unclear [40]. Many tumor-linked fac-
tors have been implicated in the onset and progression of
skeletal metastases, including IGFI and II, TGFβ, PSA,
uPA, FGF-1 and -2, bone morphogenic proteins, and ET-
1. This latter peptide stimulates mitogenesis in osteoblasts
The ET-1/ETAR autocrine pathway is biologically relevant in tumor development and progression modulating cell proliferation,  survival, angiogenesis, invasion Figure 1
The ET-1/ETAR autocrine pathway is biologically relevant in tumor development and progression modulating cell proliferation, 
survival, angiogenesis, invasion. Targeted blockade of the ETAR using the potent and selective ETAR antagonist reduces tumor 
growth which concurs with the inhibition of the tumor-induced angiogenesis and invasiveness and with the induction of massive 
tumor cell apoptosis.
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and decreases osteoclastic bone resorption and osteoclast
motility [40].
ET-1 is increased in the circulation of patients with pros-
tate cancer with osteoblastic metastases, and is also pro-
duced by breast cancer cell lines that cause osteoblastic
metastases. Treatment with the orally active ETAR antago-
nist atrasentan dramatically decreased bone metastases
and tumor burden in mice inoculated with the human
breast cancer cell line ZR-75-1 producing ET-1 [41]. The
growing list of potential clinical applications for ETAR
blockade should now include treatment and eventually
prevention of osteoblastic bone metastases.
Cervical carcinoma
Human papillomavirus (HPV)-positive human cervical
carcinoma cell lines overexpress ET-1 and ETAR mRNA
and secrete ET-1 protein compared to HPV-negative cells.
Binding studies show that HPV-infected cells express
increased numbers of functional ETAR, and a specific
antagonist of ETA inhibits ET-1-induced proliferation. An
ETBR selective antagonist had no effect. These results indi-
cate that the ET-1/ETAR axis could be targeted for antitu-
mor therapy. Thus, atrasentan inhibited the growth of
cervical carcinoma cell xenografts. Two cycles of treatment
completely reverted tumor growth. As reported for ovar-
ian cancer, this small molecule displayed additive effects
when administrated in combination with the cytotoxic
drug paclitaxel supporting its clinical use either in mono-
or combination regimens [42,43].
Breast carcinoma
ET-1 and its receptors, ETAR and ETBR, are overexpressed
in breast carcinomas. Analysis of 176 breast carcinomas
has shown that ET-1 was expressed in 43% whereas ETAR
in 46% and ETBR in 53% of the cases. Elevated expression
of ET-1 and its receptors was more common in breast car-
cinomas of patients with lower disease-free survival time
and overall survival. In particular, a statistically significant
correlation was observed between ETAR expression and
reduced disease-free survival time [44]. ET-1, ETAR and
ETBR expression was also associated with increased VEGF
expression and higher vascularity [45]. Therefore analysis
of the ET-axis and in particular of ETAR may improve the
prediction of relapse and death and may identify patients
who may profit from ETAR targeted adjuvant therapy.
Kaposi's sarcoma
A different approach in targeting ET-1 receptor in cancer
treatment is represented by Kaposi's sarcoma (KS) in
which ET-1 acts as an autocrine growth factor through
both ETAR and ETBR. Binding of ET-1 and ET-3 to both
receptors increased the proliferation, migration and inva-
siveness of the KS derived cell line, KS IMM cells, by stim-
ulating secretion and activation of multiple tumor
proteases. Treatment of KS IMM xenografts with the small
molecule ETA/ETB antagonist A182086 produced a tumor
growth inhibition most likely related to antiproliferative
effect on tumor cells and to the antiangiogenic effect on
endothelial cells expressing ETBR. Thus ET-1 receptor
antagonists may be effective for treatment of this malig-
nancy because capable of interfering simultaneously with
cell proliferation, invasiveness and angiogenesis [46,47].
Melanoma
Transformed melanocytes express both ETAR and ETBR.
Gene expression profiling [48] and immunophenotyping
of human cutaneous melanoma [49] have recently identi-
fied ETBR as critical in the progression of this malignancy.
Through the same receptor, ET-1 acts as antiapoptotic fac-
tor for melanoma cells and melanocytes. Thus, ETBR
blockade by the ETBR peptide antagonist BQ788 resulted
in growth inhibition and death of melanoma cells in vivo
and in vitro [50]. While these early studies defined a rele-
vant role of the ET-1/ETBR pathway in the biology of
melanocytic tumors, the molecular events underlying this
activity are becoming now identified. Early melanoma
growth is the result of disrupted intercellular homeostatic
regulation. Once this balance is lost and malignant trans-
formation has occurred, microenviromental factors such
as cell adherence to extracellular matrix, host-tumor inter-
actions, degradation of matrix components, migration
and invasion became essential for the tumor progression
to the metastatic phenotype. Changes in cadherins, gap
junctions and matrix metalloproteinases expression have
emerged as key factors in melanoma progression. In this
regards ET-1 and ET-3 by ETBR signalling induce the inac-
tivation of the gap junctions through the phosphorylation
of the Cx43, which are responsible for contact mediated
regulatory control of keratinocytes. Additionally, activa-
tion of ETBR pathway by ET-1 and ET-3 contributes to dis-
ruption of normal host-tumor interactions by
downregulating the expression of E-cadherin and associ-
ated  β-catenin adhesion proteins. Significant ET-1-
induced mRNA expression of the transcription factor
Snail, which has been identified a potent inhibitor of E-
cadherin expression in melanoma, closely correlates with
downregulation of E-cadherin. ETs also causes a tyrosine
phosphorylation of β-catenin which contributes to loss of
E-cadherin function, with a concomitant upregulation of
N-cadherin. This latter change can mediate homotypic
adhesive interactions as well as heterotypic melanoma
cell-cell interactions. Concurrently ETs increase αvβ3 and
α2β1 integrin expression and matrix metalloproteinase
(MMP)-2, -9, and membrane type-1-MMP activation.
These effects were associated with ETBR-mediated
enhancement of cell adhesion, migration and invasive-
ness. Due to the resistance of melanoma to current thera-
pies, the identification of molecular mechanisms
underlying local and metastatic growth is mandatory forJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/16
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the development of novel treatments. The small molecule
A-192621, an orally biovailable non peptide ETBR antag-
onist, significantly inhibited melanoma growth in nude
mice. In conclusion, because multiple molecular path-
ways, such as FAK and MAPK, elicited by ET-1 and ET-3
are triggered by the ETBR leading to the activation of all
the molecular effectors involved in melanoma progres-
sion, including integrins, tumor proteases, cell-cell adhe-
sion and communication molecules, blockade of this
receptor by small molecules results into inhibition of
melanoma growth in vitro and in vivo, thus offering an
unprecedented opportunity of targeted therapy in this
malignancy [51].
Conclusions
A large body of in vitro and in vivo studies indicate the ET
axis as a potential novel therapeutic target for cancer. ET-
1 is overexpressed in many malignancies, acting as an
autocrine/paracrine growth factor. Engagement of the
cognate receptor by ET-1 triggers tumor proliferation,
VEGF-induced angiogenesis, metastatic potential, antiap-
optotic effect and is synergistic with other growth factors.
Direct mechanistic evidence of the role of ETARs in various
malignancies supports the concept that ETAR antagonists
may significantly revert the malignant phenotype [3]. The
antitumor activity of selective ETAR antagonists observed
in preclinical studies has been strongly supported in early
clinical trials. Among these, atrasentan deserves at the
present particular attention for clinical testing, in view of
its oral bioavailability, suitable pharmacokinetic, toxicity
profile and clinical activity.
The role of the ET axis and the therapeutic relevance of ET-
1 receptor antagonists in a range of malignancies requires
future investigation that may lead to a new generation of
molecularly targeted therapies for cancer (Table 1)
[15,32,35,40-47,50-57].
Table 1: Role of ET-1 and its receptors in different malignancies
Action of ET-1 Endothelin receptors Receptor antagonists and their effects
Prostate cancer ET-1 promotes prostate cancer 
growth, inhibits apoptosis through 
the ETAR
High ETAR expression, decreased or 
absent ETBR expression, frequent 
methylation of ETBR gene
Atrasentan relieves pain, and delays time to 
clinical and biochemical progression in 
prostate cancer patients
Ovarian cancer ET-1 promotes cell proliferation 
survival, invasion and VEGF-
dependent angiogenesis through 
ETAR
ETAR mRNA is detected in 84% 
carcinoma examinated, ETBR in only 
40%. ETAR mediates all ET-1 induced 
tumor promoting effects
Atrasentant inhibits cell proliferation and 
growth of ovarian carcinoma xenografts and 
displays additive effects in combination with 
taxanes
Melanoma ET-1 and ET-3 promotes 
melanoma cell proliferation and 
invasion
ETAR are downregulated in melanoma 
cells. ETBR expression is increased in 
melanoma cells in comparison to 
benign nevi
ETBR antagonist inhibits growth of 
melanoma cells lines, and reduces human 
melanoma tumor growth in nude mice.
Bone malignancies ET-1 increases osteocalcin 
expression and new bone 
formation
Both ETAR and ETBR are expressed ETAR antagonist blocks ET-1-mediated 
effects and also inhibits progression of 
skeletal metastases in prostate cancer 
patients
Breast cancer Increased ET-1 expression 
inversely correlates with the 
degree of tumor cell differentiation
Elevated expression of ETAR are 
detected in breast cancer tissue in 
comparison to normal
Renal cancer ET-1 opposes the paclitaxel-
induced apoptosis in renal 
carcinoma cell lines
All cell lines express ETAR
Lung cancer ET-1 is detected in most squamous 
cell and adenocarcinomas
Both ETAR and ETBR are expressed; 
ETAR is downregulated in comparison 
to normal bronchial tissue
Colon cancer ET-1 protects colon carcinoma 
cells from FasL-induced apoptosis
Increased expression of ETAR and 
ETBR in neoplastic tissue
ETA/BR antagonist, inhibits cell proliferation 
and potentiates FasL-induced apoptosis of 
tumor cells
Cervical cancer ET-1 induces proliferation of HPV-
positive cervical carcinoma cell 
lines
Express both ETAR and ETBR. 
Increased expression of ETAR on 
HPV-positive cells
Atrasentan inhibits cell proliferation and 
growth of cervical carcinoma xenografts and 
displays additive effects in combination with 
taxane
Kaposi's ET-1 and ET-3 induces cell 
proliferation, migration and 
invasion
Both ETAR and ETBR are expressed ETA,BR antagonist blocks ET-1 induced cell 
proliferation and invasion and inhibits tumor 
growth in nude mice
CNS tumors ET-1 promoted meningioma cell 
proliferation
Both ETAR and ETBR are expressed BQ123 blocked ET-1-induced effects; ETAR 
antagonist had no effectJournal of Translational Medicine 2004, 2 http://www.translational-medicine.com/content/2/1/16
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Resistance to apoptosis is a principal mechanism whereby
tumors are able to overcome cytotoxicity induced by
chemotherapy. ETAR blockade sensitized tumor cells to
the apoptotic potential of chemoterapeutic agent result-
ing in tumor regression. The cooperative antitumor effect
of combination therapy in which ETAR antagonist, by
increasing the commitment of tumor cells towards apop-
tosis, potentiates the therapeutic efficacy of conventional
cytotoxic drugs, offers a rationale for its clinical evaluation
in malignancies expressing ETAR [58].
A novel approach to cancer therapy emerges by the treat-
ment with multiple selective inhibitors to different
growth factor receptors or to key post receptor signaling
pathways. Engagement of the endothelin receptor by ET-1
induces tumor-promoting effects that are mediated by dif-
ferent downstream effectors, such as EGFR, VEGF COX-2,
AKT, MAPK that could became the preferentially escaping
pathways utilized by tumor cells. In this context, concom-
itant blockade of multiple molecular targets by using
inhibitor of EGFR, or COX-2, or others in combination
with ETAR antagonist could represent an attractive thera-
peutic strategy to be explored in clinical settings.
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